Drug Utilization Review Board
Minutes Draft

Name of Meeting: Drug Utilization Review Board
Date of Meeting: May 22, 2014
Length of Meeting: 1 hour and 41 minutes
Location of Meeting: DMAS Board Room 13th Floor

Members Present:
Randy Ferrance, MD, Chair
Avtar Dhillon, MD
Jane Settle, NP, Vice Chair
Jonathan Evans, MD
Sandra Dawson, RPh
Bill Rock, PharmD
Cynthia Fagan, FNP
Wendy Nash, PharmD

Members Not Present:
Rhonda Bass, MD
Michele Thomas, PharmD
Jamie Haight, RPh
Seth Brant, MD

DMAS Attendees:
Rachel Cain, PharmD
Donna Proffitt, RPh, Pharmacy Program Manager
Bryan Tomlinson, Health Care Services Division Director
Danielle Adeeb
Tyrone Wall
Keith Hayashi, RPh
Kim Richardson

Contractors:
Donna Johnson, PharmD, Clinical Pharmacy Manager, Xerox
Tina Carter, CPhT, Pharmacy Technician

Vendors:
Nancy Eldin, PharmD, Magellan Health Services
Debbie Moody, RPh, Magellan Health Services

Visitors:
Rod Teat, Otsuka,
Cherie Robertson, Pfizer
Loren Driscoll, Boehringer Ingelheim
Bob Broach, Celgene
Kimberly Hayashi, MCV Student
Ronnie DePue, Boehringer Ingelheim
Judy Buchanan, Gilead
Paula Pitman-Kupresak, Abbvie
Carl Whitehead, Whitehead Consulting
Lisa Pompa, Vertex

Call to Order and Introductions
Dr. Ferrance called the meeting to order at 2:07pm.

Minutes—March 20, 2014
Dr. Ferrance asked if there were additions or deletions to the minutes from the March 20, 2014 meeting. Ms. Fagan made the motion for the meeting minutes to be approved as written, which was seconded by Dr. Dhillon. The Board voted unanimously to approve the minutes.

New Drugs
Anoro Ellipta® (umeclidinium/vilanterol) –Dr. Johnson presented the ProDUR and RetroDUR criteria. The motion was made to accept the criteria as written; the Board seconded and approved the criteria.

Hetlioz® (tasimelteon) – Dr. Johnson presented the ProDUR and RetroDUR criteria. The motion was made to accept the criteria as written with the addition of the drug-drug interaction (DD) of CYP3A4 inhibitors as Sev 2. The Board seconded and approved the criteria.

Orenitram® (treprostinil diolamine) – Dr. Johnson presented the ProDUR and RetroDUR criteria. The motion was made to accept the criteria as written; the Board seconded and approved the criteria.

Otezla® (apremilast) – Dr. Johnson presented the ProDUR and RetroDUR criteria. The motion was made to accept the criteria as written with the addition of the following: Daliresp® (roflumilast) as a therapeutic duplication (TD), renal impairment as Sev 2 drug to diagnosis (MC) and changing the drug-drug interaction (DD) for strong CYP 3A4 inducers to Sev 1. The Board seconded and approved the criteria.

High Cost Drugs
The Board Members discussed patient's low tolerance rates to certain high cost drugs and the approach for reducing medication waste without compromising patient safety.

The Board requested an analysis of the utilization of all High Cost Drugs and HIV drugs filled only once for review at the next meeting.

Old Business
Dr. Johnson noted that Duavee® was presented to the Board during the March meeting. The Board reviewed and approved the DUR criteria. A request was made for the comparison of this drug to other drugs for the same indication. The Board also requested more information about the osteoporosis prevention indication and how this compares to Evista®.

Dr. Johnson reported that the only medication with comparable indications is Prempro®. Since Evista® is indicated for both the prevention and treatment of

osteoporosis, it is not a comparable alternative to Duavee. After discussions with members it was decided that a Service Authorization would not be applied to Duavee®.

Reports

ProDUR and RetroDUR – Dr. Johnson reviewed the reports provided in the DUR Board binder.

Utilization Analysis Reports – Dr. Johnson reviewed the top 25 Drugs Ranked by Claim Count, by Payment Amount and the Cost of Utilization Analysis by Drug Type. She noted the **86.35%** total claim count for Generic drugs compared to the **10.30%** of Single Source Brands.

AAP Report

Dr. Johnson reviewed the report provided in the DUR Board binder. She noted the current program will be expanding to include children up to 12 years of age beginning on July 1, 2014.

Future Topics

Dr. Johnson presented the Pancreatic Enzyme Utilization report for the purpose of reviewing the claims utilization of Pancreatic Enzymes and the diagnoses of the members to determine appropriateness. Dr. Nash made the motion to send letters to doctors about diagnoses specific for this utilization. The recommendation was made to only letter those with inappropriate or missing diagnoses. The Board requested that the utilization be re-evaluated six months after the intervention to determine if a clinical service authorization is needed for this class of medications. The motion was seconded by Ms. Fagan and approved.

Additional topics were suggested by the Board. Dr. Nash recommended the Board consider preventive care solutions such as promoting utilization of the influenza vaccine for the 2014-2015 flu season by sending letters to prescribers. Dr. Dhillon suggested metabolic syndrome monitoring in patients on atypical antipsychotic medications.

Meeting was adjourned at 3:48 pm.

Future DUR Board Meetings are scheduled for August 21 and November 20, 2014.